A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy
Status:
Completed
Trial end date:
2011-10-31
Target enrollment:
Participant gender:
Summary
Concurrent chemoradiotherapy (CHRT) is the standard of care for unresectable locally advanced
stage III non-small cell lung cancer. However, the optimal combination remains unclear. The
aim of this study is to evaluate the efficacy of 2 induction chemotherapy cycles (days 1 and
22) with docetaxel 75 mg/m2 and cisplatin 75 mg/m2 followed by concurrent chemotherapy
(weekly docetaxel-cisplatin, 20 mg/m2) and 3-D conformal radiotherapy for 6 weeks (66 Gy/5
fractions per week/2 Gy per fraction). ). The primary endpoint is the response rate.
Secondary objectives are toxicity, time to progression, and overall survival.